MADD Antibody Cat. No.: 1150

Availability: In stock

$0.00

 Price Options

* Required Fields

$0.00
psi-iconSpecifications
HOST SPECIES:Rabbit
SPECIES REACTIVITY: Human, Mouse, Rat
IMMUNOGEN: MADD antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human MADD.

The immunogen is located within the last 50 amino acids of MADD.
TESTED APPLICATIONS: ELISA, ICC, IF, WB
APPLICATIONS: MADD antibody can be used for detection of MADD by Western blot at 1 - 2 mg/mL. 200 to 220 kDa bands should be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.

Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
POSITIVE CONTROL:1) Cat. No. 1201 - HeLa Cell Lysate
 2) Cat. No. 1212 - 3T3 Cell Lysate
 3) Cat. No. 10-901 - Human Spleen Tissue Slide
 4) Cat. No. 17-001 - HeLa Cell Slide
PREDICTED MOLECULAR WEIGHT: 200 to 220 kDa

psi-iconProperties
PURIFICATION:MADD Antibody is Antibody is DEAE purified.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:MADD Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:batch dependent
STORAGE CONDITIONS:MADD antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:MADD
ALTERNATE NAMES:MADD Antibody: DENN, IG20, RAB3GEP, DENN, KIAA0358, MAP kinase-activating death domain protein, Differentially expressed in normal and neoplastic cells
ACCESSION NO.:AAD12154
PROTEIN GI NO.:3289973
GENE ID:8567
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:MADD Antibody: MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1) associated protein though their death domains. Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% identity with DENN (for differentially expressed in neoplastic vs. normal cells), which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94% overall identity to a GDP/GTP exchange protein Rab3-GEP. MADD is 87% identical to KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signaling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.
REFERENCES:1) Schievella AR, Chen JH, Graham JR, Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 1997;272:12069-12075
2) Chow VT, Lee SS. DENN, a novel human gene differentially expressed in normal and neoplastic cells. DNA Seq 1996;6:263-273
3) Zhang Y, Zhou L, Miller CA. A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system. Proc Natl Acad Sci U S A 1998;95:2586-2591
4) Brown TL and Howe PH. MADD is highly homologous to a Rab3 guanine-nucleotide exchange protein (Rab3-GEP). Curr Biol 1998;8:R191

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.